图片来源:(已获授权)香港迈极康医疗中心 参考资料:MODERNA ANNOUNCES MRNA-1345, AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, HAS MET PRIMARY EFFICACY ENDPOINTS IN PHASE 3 TRIAL IN OLDER ADULTS 版权/免责说明:本文来自香港迈极康医疗内容团队,欢迎个人转发至朋友圈。香港迈极康医疗内容团队专...
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV)Vaccine网页链接 关于禹杭资本 Moonbay capital 禹杭资本于2017年在美国旧金山成立,2019年正式进入中国,设有美元基金和人民币基金,是一家专注于医疗创新及信息技术产业领域投资的全球性投资公司。禹杭资本...
参考资料:MODERNA ANNOUNCES MRNA-1345, AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, HAS MET PRIMARY EFFICACY ENDPOINTS IN PHASE 3 TRIAL IN OLDER ADULTS 版权/免责说明:本文来自香港迈极康医疗内容团队,欢迎个人转发至朋友圈。香港迈极康医疗内容团队专注介绍传播最新医药学术资讯。本文仅作信息...
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adul...
Interim findings are presented from a phase 3 trial evaluating mRNA-1345 revaccination at 12 months after a primary dose in adults aged 鈮 50 years. Figure 1. METHODS. Part C of a multi-part, ongoing, phase 3 trial (NCT05330975) evaluated the safety, tolerability, and immunogenicity of ...
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV)Vaccinehttps://www.businesswire.com/news/home/20211118005257/en/ 关于禹杭资本 Moonbay capital 禹杭资本于2017年在美国旧金山成立,2019年正式进入中国,设有美元基金和人民币基金,是一家专注于医疗创...